Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
GSK starts phase III study of once-daily closed triple combination therapy FF/UMEC/VI in patients with asthma
The start of a phase III study investigating the effects of once-daily closed triple combination therapy (FF/UMEC/VI).
Read more -
GSK announces Board changes
the creation of a new Board committee and a number of changes to the membership of the Board and its committees
Read more -
ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen
First phase III studies to show efficacy of two-drug regimen as maintenance therapy
Read more -
ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for Tivicay® (dolutegravir) in children and adolescents living with HIV in Europe
The CHMP has adopted a positive opinion to reduce the weight and age limit for the treatment of HIV with Tivicay.
Read more -
GSK submits regulatory application in Japan for belimumab in systemic lupus erythematosus
Belimumab is a human monoclonal antibody that selectively targets B-lymphocyte stimulator an important factor in the survival of B cells.
Read more -
GSK opens new global vaccines R&D center in Rockville, MD, USA
New state-of-the-art facility will house 450 scientists and support staff, creating up to 200 new jobs.
Read more -
Dominique Limet to step down as CEO of ViiV Healthcare; Deborah Waterhouse to succeed him
After seven years as CEO of ViiV Healthcare, Dr Dominique Limet will step down at the end of March 2017.
Read more -
Relvar® Ellipta® 100/25 mcg gains approval in Japan for use in patients with COPD
Relvar is a combination of the inhaled corticosteroid, fluticasone furoate, and the long-acting beta2 agonist, vilanterol ‘VI’.
Read more -
GSK files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
The filing by GSK of a regulatory submission closed triple combination therapy FF/UMEC/VI 100/62.5/25 mcg for patients with COPD.
Read more -
GSK announces EU regulatory submission of candidate vaccine for prevention of shingles - Follows regulatory submissions in US and Canada
Tthe regulatory submission of a MMA to the EMA seeking approval for ShingrixTM.
Read more -
GSK starts phase III programme with daprodustat for anaemia associated with chronic kidney disease
The start of a phase III development programme investigating daprodustat as a treatment for anaemia associated with CKD.
Read more -
GSK announces phase lll study of mepolizumab meets co-primary endpoints and all secondary endpoints in patients with eosinophilic granulomatosis with polyangiitis
Both co-primary endpoints and all secondary endpoints were met in a pivotal phase III study.
Read more -
GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
COPD is a disease of the lungs that includes chronic bronchitis, emphysema or both.
Read more -
ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders
Read more -
GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older
An approval from the US Food and Drug Administration’s (FDA) Center
Read more -
GSK announces new data from phase III studies of sirukumab in adult patients with moderately to severely active rheumatoid arthritis
Sirukumab is being co-developed as part of a collaboration with Janssen Biologics (Ireland) [Janssen].
Read more -
GSK’s Benlysta® (belimumab) shows sustained benefits in patients with SLE
GSK today announced results from a 7-year safety and efficacy continuation study for Benlysta® (belimumab).
Read more -
GSK leads Access to Medicine Index 2016
GSK has today been ranked first in the Access to Medicine Index for the fifth consecutive time.
Read more -
GSK announces positive results in fourth consecutive pivotal trial of Benlysta® (belimumab) in SLE
Data in Japan, China and South Korea will form basis of new regulatory submissions for Benlysta
Read more -
GSK statement in response to New York Times article on China
These matters relating to our operations in China were deeply disappointing to GSK.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
